Intrinsic value of MiMedx Group - MDXG

Previous Close

$6.22

  Intrinsic Value

$5.86

stock screener

  Rating & Target

hold

-6%

Previous close

$6.22

 
Intrinsic value

$5.86

 
Up/down potential

-6%

 
Rating

hold

We calculate the intrinsic value of MDXG stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.7

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  31.30
  28.67
  26.30
  24.17
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.25
  12.43
  11.69
  11.02
  10.41
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
  7.33
  7.10
  6.89
  6.70
  6.53
  6.38
  6.24
Revenue, $m
  322
  414
  523
  649
  794
  957
  1,138
  1,338
  1,557
  1,793
  2,047
  2,318
  2,607
  2,911
  3,232
  3,569
  3,921
  4,289
  4,673
  5,072
  5,488
  5,920
  6,370
  6,837
  7,322
  7,826
  8,351
  8,896
  9,463
  10,054
Variable operating expenses, $m
  278
  357
  449
  557
  680
  819
  973
  1,144
  1,329
  1,531
  1,743
  1,974
  2,219
  2,478
  2,751
  3,038
  3,338
  3,651
  3,978
  4,318
  4,672
  5,040
  5,422
  5,820
  6,233
  6,662
  7,109
  7,573
  8,056
  8,558
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  278
  357
  449
  557
  680
  819
  973
  1,144
  1,329
  1,531
  1,743
  1,974
  2,219
  2,478
  2,751
  3,038
  3,338
  3,651
  3,978
  4,318
  4,672
  5,040
  5,422
  5,820
  6,233
  6,662
  7,109
  7,573
  8,056
  8,558
Operating income, $m
  44
  57
  73
  92
  114
  138
  165
  195
  227
  262
  305
  345
  388
  433
  481
  531
  583
  638
  695
  754
  816
  881
  947
  1,017
  1,089
  1,164
  1,242
  1,323
  1,408
  1,495
EBITDA, $m
  52
  67
  85
  106
  129
  156
  186
  218
  254
  292
  334
  378
  425
  475
  527
  582
  639
  699
  762
  827
  895
  965
  1,038
  1,114
  1,194
  1,276
  1,361
  1,450
  1,543
  1,639
Interest expense (income), $m
  0
  0
  1
  2
  4
  5
  7
  9
  12
  15
  17
  21
  24
  28
  31
  35
  40
  44
  49
  54
  59
  64
  70
  75
  81
  88
  94
  101
  108
  115
  122
Earnings before tax, $m
  44
  56
  71
  89
  108
  131
  155
  183
  213
  245
  284
  321
  360
  402
  445
  491
  539
  589
  641
  696
  752
  811
  872
  936
  1,002
  1,070
  1,141
  1,215
  1,293
  1,373
Tax expense, $m
  12
  15
  19
  24
  29
  35
  42
  49
  57
  66
  77
  87
  97
  108
  120
  133
  146
  159
  173
  188
  203
  219
  235
  253
  270
  289
  308
  328
  349
  371
Net income, $m
  32
  41
  52
  65
  79
  95
  114
  133
  155
  179
  207
  234
  263
  293
  325
  359
  393
  430
  468
  508
  549
  592
  637
  683
  731
  781
  833
  887
  944
  1,002

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  254
  326
  412
  512
  626
  754
  898
  1,055
  1,228
  1,414
  1,614
  1,828
  2,056
  2,296
  2,549
  2,814
  3,092
  3,382
  3,685
  4,000
  4,328
  4,669
  5,023
  5,392
  5,774
  6,172
  6,586
  7,016
  7,463
  7,929
Adjusted assets (=assets-cash), $m
  254
  326
  412
  512
  626
  754
  898
  1,055
  1,228
  1,414
  1,614
  1,828
  2,056
  2,296
  2,549
  2,814
  3,092
  3,382
  3,685
  4,000
  4,328
  4,669
  5,023
  5,392
  5,774
  6,172
  6,586
  7,016
  7,463
  7,929
Revenue / Adjusted assets
  1.268
  1.270
  1.269
  1.268
  1.268
  1.269
  1.267
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
  1.268
Average production assets, $m
  34
  44
  56
  69
  85
  102
  122
  143
  167
  192
  219
  248
  279
  311
  346
  382
  420
  459
  500
  543
  587
  633
  682
  732
  783
  837
  894
  952
  1,013
  1,076
Working capital, $m
  54
  70
  88
  110
  134
  162
  192
  226
  263
  303
  346
  392
  441
  492
  546
  603
  663
  725
  790
  857
  927
  1,001
  1,076
  1,155
  1,237
  1,323
  1,411
  1,503
  1,599
  1,699
Total debt, $m
  19
  42
  68
  99
  135
  175
  220
  269
  323
  381
  443
  510
  581
  656
  735
  818
  904
  995
  1,089
  1,188
  1,290
  1,396
  1,507
  1,622
  1,741
  1,865
  1,994
  2,129
  2,268
  2,413
Total liabilities, $m
  79
  102
  129
  160
  195
  235
  280
  329
  383
  441
  504
  570
  641
  716
  795
  878
  965
  1,055
  1,150
  1,248
  1,350
  1,457
  1,567
  1,682
  1,802
  1,926
  2,055
  2,189
  2,328
  2,474
Total equity, $m
  175
  225
  284
  352
  431
  519
  618
  726
  845
  973
  1,111
  1,258
  1,414
  1,580
  1,754
  1,936
  2,127
  2,327
  2,535
  2,752
  2,978
  3,212
  3,456
  3,710
  3,973
  4,246
  4,531
  4,827
  5,135
  5,455
Total liabilities and equity, $m
  254
  327
  413
  512
  626
  754
  898
  1,055
  1,228
  1,414
  1,615
  1,828
  2,055
  2,296
  2,549
  2,814
  3,092
  3,382
  3,685
  4,000
  4,328
  4,669
  5,023
  5,392
  5,775
  6,172
  6,586
  7,016
  7,463
  7,929
Debt-to-equity ratio
  0.110
  0.190
  0.240
  0.280
  0.310
  0.340
  0.360
  0.370
  0.380
  0.390
  0.400
  0.410
  0.410
  0.420
  0.420
  0.420
  0.430
  0.430
  0.430
  0.430
  0.430
  0.430
  0.440
  0.440
  0.440
  0.440
  0.440
  0.440
  0.440
  0.440
Adjusted equity ratio
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688
  0.688

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  32
  41
  52
  65
  79
  95
  114
  133
  155
  179
  207
  234
  263
  293
  325
  359
  393
  430
  468
  508
  549
  592
  637
  683
  731
  781
  833
  887
  944
  1,002
Depreciation, amort., depletion, $m
  9
  10
  12
  14
  16
  18
  21
  23
  27
  30
  29
  33
  37
  42
  46
  51
  56
  61
  67
  72
  78
  84
  91
  98
  104
  112
  119
  127
  135
  143
Funds from operations, $m
  41
  51
  64
  78
  95
  113
  134
  157
  182
  209
  236
  267
  300
  335
  371
  409
  449
  491
  535
  580
  627
  676
  727
  780
  836
  893
  952
  1,014
  1,079
  1,146
Change in working capital, $m
  13
  16
  18
  21
  24
  28
  31
  34
  37
  40
  43
  46
  49
  51
  54
  57
  60
  62
  65
  68
  70
  73
  76
  79
  82
  85
  89
  92
  96
  100
Cash from operations, $m
  28
  36
  45
  57
  70
  86
  103
  123
  145
  169
  194
  221
  251
  283
  317
  353
  390
  429
  470
  513
  557
  603
  652
  702
  754
  808
  864
  922
  983
  1,046
Maintenance CAPEX, $m
  -3
  -5
  -6
  -7
  -9
  -11
  -14
  -16
  -19
  -22
  -26
  -29
  -33
  -37
  -42
  -46
  -51
  -56
  -61
  -67
  -72
  -78
  -84
  -91
  -98
  -104
  -112
  -119
  -127
  -135
New CAPEX, $m
  -8
  -10
  -12
  -14
  -15
  -17
  -19
  -21
  -23
  -25
  -27
  -29
  -31
  -33
  -34
  -36
  -38
  -39
  -41
  -43
  -44
  -46
  -48
  -50
  -52
  -54
  -56
  -58
  -61
  -63
Cash from investing activities, $m
  -11
  -15
  -18
  -21
  -24
  -28
  -33
  -37
  -42
  -47
  -53
  -58
  -64
  -70
  -76
  -82
  -89
  -95
  -102
  -110
  -116
  -124
  -132
  -141
  -150
  -158
  -168
  -177
  -188
  -198
Free cash flow, $m
  16
  21
  28
  36
  46
  57
  70
  85
  102
  121
  141
  163
  188
  213
  241
  270
  301
  334
  368
  403
  440
  479
  519
  561
  604
  649
  696
  745
  795
  848
Issuance/(repayment) of debt, $m
  19
  23
  27
  31
  36
  40
  45
  49
  54
  58
  63
  67
  71
  75
  79
  83
  87
  91
  94
  98
  102
  106
  111
  115
  119
  124
  129
  134
  140
  145
Issuance/(repurchase) of shares, $m
  10
  9
  7
  4
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  29
  32
  34
  35
  36
  40
  45
  49
  54
  58
  63
  67
  71
  75
  79
  83
  87
  91
  94
  98
  102
  106
  111
  115
  119
  124
  129
  134
  140
  145
Total cash flow (excl. dividends), $m
  45
  53
  62
  71
  81
  97
  115
  135
  156
  179
  203
  230
  258
  288
  320
  353
  388
  424
  462
  502
  543
  585
  630
  676
  723
  773
  825
  879
  935
  993
Retained Cash Flow (-), $m
  -42
  -50
  -59
  -69
  -78
  -88
  -98
  -109
  -119
  -128
  -138
  -147
  -156
  -165
  -174
  -183
  -191
  -200
  -208
  -217
  -226
  -235
  -244
  -253
  -263
  -274
  -284
  -296
  -308
  -320
Prev. year cash balance distribution, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  3
  3
  3
  2
  3
  9
  17
  26
  38
  51
  65
  83
  102
  123
  146
  171
  197
  225
  254
  285
  317
  351
  386
  422
  460
  500
  540
  583
  627
  673
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  3
  3
  2
  2
  2
  6
  11
  16
  22
  27
  31
  35
  39
  41
  43
  43
  43
  41
  39
  36
  33
  29
  25
  22
  18
  15
  12
  9
  7
  5
Current shareholders' claim on cash, %
  98.6
  97.6
  97.0
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8
  96.8

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

FINANCIAL RATIOS  of  MiMedx Group (MDXG)

Valuation Ratios
P/E Ratio 56.9
Price to Sales 2.8
Price to Book 5.1
Price to Tangible Book
Price to Cash Flow 26.3
Price to Free Cash Flow 36
Growth Rates
Sales Growth Rate 31%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 18.5%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 7.3%
Ret/ On Assets - 3 Yr. Avg. 12.4%
Return On Total Capital 10%
Ret/ On T. Cap. - 3 Yr. Avg. 15.6%
Return On Equity 10%
Return On Equity - 3 Yr. Avg. 15.6%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 86.9%
Gross Margin - 3 Yr. Avg. 88.7%
EBITDA Margin 9.4%
EBITDA Margin - 3 Yr. Avg. 10.5%
Operating Margin 7.3%
Oper. Margin - 3 Yr. Avg. 8.7%
Pre-Tax Margin 7.3%
Pre-Tax Margin - 3 Yr. Avg. 8.7%
Net Profit Margin 4.9%
Net Profit Margin - 3 Yr. Avg. 8.5%
Effective Tax Rate 33.3%
Eff/ Tax Rate - 3 Yr. Avg. 8.9%
Payout Ratio 0%

MDXG stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDXG stock intrinsic value calculation we used $245.015 million for the last fiscal year's total revenue generated by MiMedx Group. The default revenue input number comes from 0001 income statement of MiMedx Group. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDXG stock valuation model: a) initial revenue growth rate of 31.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MDXG is calculated based on our internal credit rating of MiMedx Group, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of MiMedx Group.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDXG stock the variable cost ratio is equal to 86.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDXG stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for MiMedx Group.

Corporate tax rate of 27% is the nominal tax rate for MiMedx Group. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDXG stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDXG are equal to 10.7%.

Life of production assets of 7.5 years is the average useful life of capital assets used in MiMedx Group operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDXG is equal to 16.9%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $133 million for MiMedx Group - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 110.835 million for MiMedx Group is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of MiMedx Group at the current share price and the inputted number of shares is $0.7 billion.

RELATED COMPANIES Price Int.Val. Rating
IART Integra LifeSc 49.80 59.90  hold
ZBH Zimmer Biomet 112.95 87.03  sell
CUTR Cutera 17.83 38.15  hold

COMPANY NEWS

▶ [$$] MiMedx Called on Two Lawmakers for Help Before Its Accounting Scandal   [Dec-11-18 07:25PM  The Wall Street Journal]
▶ [$$] MiMedx to Shed Jobs as Part of Overhaul   [Dec-06-18 08:12AM  The Wall Street Journal]
▶ [$$] MiMedx to Shed Jobs as Part of Overhaul   [Dec-05-18 07:27PM  The Wall Street Journal]
▶ [$$] Help Wanted, Get in on Ground Floor   [10:12AM  The Wall Street Journal]
▶ 4 Healthcare Stocks You Should Get To Know Before 2019   [Nov-20-18 09:05AM  ACCESSWIRE]
▶ [$$] Nasdaq to Delist MiMedx Amid Financial Probe   [02:16PM  The Wall Street Journal]
▶ MiMedx founder and former CEO Pete Petit prepares for battle   [Oct-10-18 07:28AM  American City Business Journals]
▶ [$$] MiMedx Kept Cheaper Products Out of Its Offerings to VA Hospitals   [Oct-07-18 08:13PM  The Wall Street Journal]
▶ [$$] MiMedx Kept Cheaper Products Out of Its Offerings to VA Hospitals   [Oct-05-18 05:30AM  The Wall Street Journal]
▶ Here's Why MiMedx Group, Inc. Gained 16.6% in September   [Oct-04-18 08:48PM  Motley Fool]
▶ How to Identify a Perfect Short Target   [Sep-25-18 01:11PM  GuruFocus.com]
▶ MiMedx Stock Shoots Higher After Earlier Drop   [Sep-21-18 03:36PM  InvestorPlace]
▶ [$$] Former MiMedx Executives to Lose Compensation   [08:30PM  The Wall Street Journal]
▶ MiMedx Announces Nasdaq Listing Extension   [05:15PM  PR Newswire]
▶ Here's Why MiMedx Group Inc. Rose 24.7% in August   [Sep-10-18 12:44PM  Motley Fool]
▶ [$$] Health Insurer Shuns Amniotic-Tissue Product From MiMedx   [Aug-15-18 10:47PM  The Wall Street Journal]
▶ [$$] Insurer Stops Reimbursing for Some MiMedx Products   [Aug-14-18 08:42PM  The Wall Street Journal]
▶ [$$] Insurer Stops Reimbursing for Some MiMedx Products   [07:11PM  The Wall Street Journal]
▶ Here's Why MiMedx Group Inc. Stock Is Falling Today   [Jul-27-18 03:00PM  Motley Fool]
▶ [$$] MiMedx Gets Delisting Notice From Nasdaq   [Jul-26-18 07:20PM  The Wall Street Journal]
▶ MiMedx Announces Receipt of Nasdaq Letter   [05:00PM  PR Newswire]
▶ [$$] Highflying Medical Firm, a Help to Wounded Veterans, Falls to Earth   [Jul-23-18 12:18PM  The Wall Street Journal]
▶ 2 Biotech Stocks at New Lows. Can They Recover?   [Jul-05-18 09:47AM  Motley Fool]
▶ Pete Petit out as MiMedx CEO, company's COO also resigns   [12:01PM  American City Business Journals]
▶ Should You Be Holding MiMedx Group Inc (NASDAQ:MDXG)?   [Jun-19-18 01:33PM  Simply Wall St.]
▶ MiMedx to Restate Years of Financial Statements   [Jun-07-18 02:38PM  The Wall Street Journal]
▶ Hedge Fund Sues MiMedx Over Short-Selling Claims   [Jun-04-18 03:47PM  Bloomberg]
▶ Why MiMedx Group Shares Rallied as Much as 24% Today   [May-23-18 04:44PM  Motley Fool]
▶ MiMedx Receives NASDAQ Notice of Late Form 10-Q Filing   [May-18-18 04:30PM  PR Newswire]
▶ Why MiMedx Group Inc. Stock Fell Today   [May-09-18 04:32PM  Motley Fool]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.